Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
Clinical trial NCT06353386 · RECRUITING
Trial details
- NCT number
- NCT06353386
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-05-20
- Primary completion
- 2029-01-15
- Enrollment
- 220
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.